drugset / Trial / NCT00357734

Iressa Follow-up Trial

NCT00357734

Phase 3 Completed 14 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).

Timeline

Start
2005-01
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule 250 mg
Subject Gefitinib Small molecule 500 mg